The Bon Secours Surgery Partners acquisition moved from rumour to signed deal on 26 October 2026, with a price below the figure first reported. Surgery Partners said it signed a definitive agreement to be acquired by HealthSpan Partners, a contractual affiliate of Bon Secours Mercy Health, for USD 23.50 per share in cash and an enterprise value of about USD 5.7 billion. Earlier reports had put the deal at roughly USD 6 billion including debt and said it was still in talks. Closing is expected in the first quarter of 2027.
Key takeaways from the Bon Secours Surgery Partners acquisition
- Price: USD 23.50 per share in cash, paid to shareholders other than affiliates of Bain Capital.
- Premium: 64% over the 30-day volume-weighted average share price before the announcement, according to the company.
- Enterprise value: about USD 5.7 billion including debt; equity value was not disclosed.
- Bain Capital, the largest shareholder, signed a voting and support agreement to vote in favour.
- Expected closing: first quarter of 2027, subject to shareholder and regulatory approvals.
How the Bon Secours Surgery Partners acquisition differs from the earlier reports
The brief for this story described talks in which Bon Secours Mercy Health was nearing a majority stake in Surgery Partners at about USD 6 billion including debt, with an announcement possible on Monday and Bain Capital keeping its nearly 40% stake. That Monday has passed. The company’s regulatory filing shows the deal was announced on 26 October at an enterprise value of about USD 5.7 billion, a little below the reported USD 6 billion, and with the buyer named as HealthSpan Partners, which the filing describes as an affiliate of Bon Secours Mercy Health.
One report published before the announcement put the price at about USD 20 a share; the signed price is USD 23.50, which is 17.5% higher by our own calculation. The filing does not confirm the 40% figure for Bain’s retained stake or give Bon Secours’ ownership percentage, so we treat those as unconfirmed.
Terms of the Bon Secours Surgery Partners acquisition
- Buyer: HealthSpan Partners, a diversified healthcare services organisation affiliated with Bon Secours Mercy Health.
- Structure: an all-cash take-private; a proxy statement and a Schedule 13E-3 will be filed with the US Securities and Exchange Commission.
- Conditions: approval by Surgery Partners shareholders, regulatory approvals and customary closing conditions.
- Financing details were not given in the filing we read.
The company’s announcement is filed with the US Securities and Exchange Commission. Eric Evans, chief executive, called it an important milestone, and Dave Doherty, chief financial officer, described a compelling premium and noted that Bain Capital is the largest shareholder.
Who the companies are in the Bon Secours Surgery Partners acquisition
Surgery Partners is a publicly listed operator of 176 surgical centres and hospitals across 30 US states, focused on outpatient procedures, according to a report on the talks; its site is surgerypartners.com. Bon Secours Mercy Health is a US nonprofit health system that operates 47 hospitals across the United States and Ireland and reportedly had about USD 14 billion in revenue last year; see bsmhealth.org. Bain Capital has held a minority stake in Surgery Partners since 2017, according to the same report.
Timeline of the Bon Secours Surgery Partners acquisition
- 2017: Bain Capital takes a minority interest in Surgery Partners.
- 2025: Bain proposes buying the remaining shares at about USD 6.7 billion including debt; talks end without a deal.
- 25 October 2026: reports say Bon Secours is in late-stage talks at about USD 6 billion.
- 26 October 2026: definitive agreement announced.
- First quarter of 2027: expected closing.
Why outpatient surgery is attracting deals
Outpatient surgery centres perform procedures that once required a hospital stay, usually at lower cost. Health systems are buying or partnering with them to expand capacity and keep patients within their networks. The report on the talks cites Ascension’s USD 3.9 billion acquisition of Amsurg earlier this year and Ensemble’s sale of a majority stake to Thoreau Group at an USD 11.75 billion valuation as comparable deals; those figures are as reported and we have not verified them. See our Healthcare Services coverage.
General background: what a take-private means
In a take-private, a listed company is bought and its shares are delisted. Public shareholders receive cash, while existing large holders may roll over some of their stake. Because a major shareholder is involved, a special committee and a Schedule 13E-3 filing are typical safeguards. Whether those apply here in detail is for the proxy statement to show.
Our analysis of the Bon Secours Surgery Partners acquisition
In our assessment, the Bon Secours Surgery Partners acquisition is notable because a nonprofit health system, through an affiliate, is taking control of a large for-profit outpatient surgery operator. A 64% premium suggests the shares had been depressed: a report said they had fallen about 31% over the past year. The lower final enterprise value than first reported does not change the strategic logic, which is vertical integration of surgical capacity.
We do not give investment advice and do not predict whether shareholders or regulators will approve.
What is not disclosed about the Bon Secours Surgery Partners acquisition
- Equity value and Bon Secours’ ownership percentage.
- Bain Capital’s retained stake and terms.
- Financing sources.
- Plans for management, facilities and physician partners.
Risks and caveats of the Bon Secours Surgery Partners acquisition
The transaction has not closed and requires shareholder and regulatory approval. Some figures come from a company filing and others from press reports of the talks, and they differ. This article is news reporting and not investment advice.
What to watch next after the Bon Secours Surgery Partners acquisition
- The proxy statement and Schedule 13E-3.
- Shareholder and regulatory decisions.
- Disclosure of Bain’s arrangement.
- Further deals between health systems and surgery operators.
FAQ
What is the price in the Bon Secours Surgery Partners acquisition?
USD 23.50 per share in cash, an enterprise value of about USD 5.7 billion.
Who is buying Surgery Partners?
HealthSpan Partners, an affiliate of Bon Secours Mercy Health.
When will it close?
The company expects the first quarter of 2027.
How we reported this: we relied on the company’s regulatory filing and press reports of the talks, and attributed every claim. Last updated 27 October 2026. This is news reporting and not advice.